Geldanamycin and its derivatives as Hsp90 inhibitors

Citations Over TimeTop 10% of 2012 papers

Abstract

The Hsp90 molecule, one of the most abundant heat shock proteins in mammalian cells, maintains homeostasis and prevents stress-induced cellular damage. Hsp90 is expressed under normal conditions at a level of about 1-2 Percent of total proteins, while its expression increases 2-10 fold in cancer cells. The two main constitutively expressed isoforms of Hsp90 are known as Hsp90-alpha and Hsp90-beta, and their upregulation is associated with tumor progression, invasion and formation of metastases, as well as development of drug resistance. The Hsp90 is a key target for many newly established, potent anticancer agents containing Hsp90 N-terminal ATP binding inhibitors, such as geldanamycin, and its analogues 17AAG and 17DMAG. The therapeutic usage of geldanamycin has been limited due to its poor water solubility and severe hepatotoxicity. Therefore, its analogues, including 17AAG, 17DMAG, Tanespimycin and Retaspimycin hydrochloride, with improved pharmacokinetic profiles, have been developed.

Related Papers

• → Hsp-90-associated oncoproteins: multiple targets of geldanamycin and its analogs(2002)236 cited
• → Heat Shock Proteins: A Potential Anticancer Target(2011)34 cited
• → Development of VER-50589 analogs as novel Hsp90 inhibitors(2023)1 cited
• → Stable disease for four years in metastatic malignant melanoma treated with the heat shock protein inhibitor 17-AAG(2006)
• → 81 Potential clinical application of a novel Heat Shock Protein 90 inhibitor CH5164840: preclinical efficacy in mono therapy and combination therapy(2010)